
Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease
Keywords: آه; US-FDA; United States Food and Drugs Administration; AD; Alzheimer's disease; ACh; acetylcholine; PAM; positive allosteric modulator; mAChR; muscarinic acetylcholine receptor; AChE; acetylcholine esterase; LDC; lipid drug conjugate; NP; nanoparticle; GP